このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

PharmaCyte Biotech 将来の成長

Future 基準チェック /06

現在、 PharmaCyte Biotechの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長	24.2%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Mar 22

PharmaCyte Biotech says CEO to step down, announces strategic review of business

Oct 07

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Aug 15

Is This A Good Time To Invest In PharmaCyte?

Jan 07

PharmaCyte Biotech: Buy The 'Dump'

Aug 21

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、PharmaCyte Biotech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

NasdaqCM:PMCB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
1/31/2024	N/A	-15	-2	-2	N/A
10/31/2023	N/A	-10	-2	-2	N/A
7/31/2023	N/A	-10	-2	-2	N/A
4/30/2023	N/A	-4	-4	-4	N/A
1/31/2023	N/A	-6	-5	-5	N/A
10/31/2022	N/A	-6	-4	-4	N/A
7/31/2022	N/A	-5	-4	-4	N/A
4/30/2022	N/A	-4	-4	-4	N/A
1/31/2022	N/A	-4	-4	-4	N/A
10/31/2021	N/A	-4	-4	-4	N/A
7/31/2021	N/A	-4	-4	-4	N/A
4/30/2021	N/A	-4	-3	-3	N/A
1/31/2021	N/A	-3	-3	-3	N/A
10/31/2020	N/A	-3	-3	-3	N/A
7/31/2020	N/A	-4	-2	-2	N/A
4/30/2020	N/A	-4	-2	-2	N/A
1/31/2020	N/A	-4	-2	-2	N/A
10/31/2019	N/A	-4	-3	-3	N/A
7/31/2019	N/A	-4	-3	-3	N/A
4/30/2019	N/A	-4	-3	-3	N/A
1/31/2019	N/A	-4	-4	-4	N/A
10/31/2018	N/A	-6	-4	-4	N/A
7/31/2018	N/A	-6	-5	-5	N/A
4/30/2018	N/A	-7	-5	-5	N/A
1/31/2018	N/A	-7	-5	-5	N/A
10/31/2017	N/A	-6	N/A	-4	N/A
7/31/2017	N/A	-5	N/A	-3	N/A
4/30/2017	N/A	-4	N/A	-3	N/A
1/31/2017	N/A	-4	N/A	-4	N/A
10/31/2016	N/A	-5	N/A	-4	N/A
7/31/2016	N/A	-6	N/A	-4	N/A
4/30/2016	N/A	-6	N/A	-4	N/A
1/31/2016	N/A	-8	N/A	-4	N/A
10/31/2015	N/A	-7	N/A	-4	N/A
7/31/2015	N/A	-10	N/A	-5	N/A
4/30/2015	N/A	-10	N/A	-5	N/A
1/31/2015	N/A	-24	N/A	-4	N/A
10/31/2014	N/A	-23	N/A	-4	N/A
7/31/2014	N/A	-24	N/A	-2	N/A
4/30/2014	N/A	-27	N/A	-2	N/A
1/31/2014	N/A	-11	N/A	-1	N/A
10/31/2013	0	-11	N/A	-1	N/A
7/31/2013	0	-6	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PMCBの予測収益成長が貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: PMCBの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: PMCBの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: PMCBの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: PMCBの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PMCBの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

PharmaCyte Biotech 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for 7,750,000 shares, for $25.19 million.

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

PharmaCyte Biotech, Inc. Announces Management Changes

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech, Inc. Announces Board Appointments

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Iroquois Capital Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech

PharmaCyte Biotech, Inc. Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech, Inc. Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Iroquois Capital Commences Consent Solicitation to Reconstitute Pharmacyte Biotech Board of Directors

Iroquois Capital Issues a Statement in Response to Pharmacyte Biotech

Iroquois Capital Delivers Open Letter to Pharmacyte Biotech Board of Directors

PharmaCyte Biotech, Inc., Annual General Meeting, Aug 25, 2022

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Initiates Studies to Confirm its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. Appoints Matthias Löhr to the Board

PharmaCyte Biotech Receives A Notification Letter from Regulation Department of the Nasdaq Stock Market

PharmaCyte Biotech, Inc. Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech, Inc Updates Status of Investigational New Drug Application to FDA

Is This A Good Time To Invest In PharmaCyte?

Pharmacyte Biotech, Inc. Study Proves Capsule Material Is Not Toxic for Encapsulated Cells

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech, Inc. Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech, Inc. Announces Encapsulation Material Does Not Alter Cellular DNA

Pharmacyte Biotech, Inc. Releases More Positive Results from U.S. Food and Drug Administration-Required Biocompatibility Tests

Pharmacyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

PharmaCyte Biotech: Buy The 'Dump'

PharmaCyte Biotech Common Stock Deleted from Other OTC

PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

PharmaCyte Biotech, Inc. Announces Update on Study Progress

PharmaCyte Biotech, Inc. Announces Stability Test Results on Cells from Master Cell Bank

PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold

PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for Its Clinical Trial Product

PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for Its Clinical Trial Product

PharmaCyte Biotech, Inc. Successfully Completes 9-Month Stability Study

PharmaCyte Biotech, Inc. Receives U.S. FDA Clinical Hold Letter

PharmaCyte Biotech, Inc. Announces Dr. Gerald W. Crabtree Will No Longer Serve as Chief Operating Officer But Instead Will Serve as Chief Scientific Officer

U.S. FDA Places PharmaCyte Biotech, Inc.’s Investigational New Drug Application on Hold

PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

PharmaCyte Biotech, Inc. Successfully Completes Six-Month Stability Study

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘